Immunogenic anti-cancer chemotherapy as an emerging concept
- PMID: 18573339
- DOI: 10.1016/j.coi.2008.05.008
Immunogenic anti-cancer chemotherapy as an emerging concept
Abstract
Tumors can acquire mutations or hijack regulatory pathways of the host immune system to render them resistant to immune attack. Standard first line therapies such as chemotherapy and radiation were not thought to provoke natural immunity to cancer, but recent findings demonstrating that dying tumor cells present and release key signals to stimulate or evade neighboring leukocytes are challenging that view. Killing tumor cells in a manner that provides danger signals and tumor antigens in the right context promotes the engagement of innate and adaptive immunity; however, this response alone will not be effective against established cancer. Coincidently driving the immune response with specific monoclonal antibodies and other immunomodulators that activate and mature dendritic cells and co-stimulate T cells and other lymphocytes is one approach. Additionally releasing immune checkpoints and inhibiting tumor-derived molecules that prevent effective tumor immunity is another. Combined these approaches have enormous potential to improve the current outcomes from conventional cancer therapy.
Similar articles
-
Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.Handb Exp Pharmacol. 2008;(181):291-328. doi: 10.1007/978-3-540-73259-4_13. Handb Exp Pharmacol. 2008. PMID: 18071951 Review.
-
[Immunological aspects of anticancer chemotherapy].Bull Acad Natl Med. 2008 Oct;192(7):1469-87; discussion 1487-9. Bull Acad Natl Med. 2008. PMID: 19445369 French.
-
Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all.Cell Death Differ. 2008 Jan;15(1):13-20. doi: 10.1038/sj.cdd.4402255. Epub 2007 Nov 16. Cell Death Differ. 2008. PMID: 18007666 Review.
-
Dendritic cells and their role in cancer immunotherapy.Iran J Immunol. 2007 Sep;4(3):127-44. Iran J Immunol. 2007. PMID: 17767012 Review.
-
The 'kiss of death' by dendritic cells to cancer cells.Cell Death Differ. 2008 Jan;15(1):58-69. doi: 10.1038/sj.cdd.4402235. Epub 2007 Oct 19. Cell Death Differ. 2008. PMID: 17948029 Review.
Cited by
-
Chemoresistance in Breast Cancer Patients Associated With Changes in P2X7 and A2A Purinergic Receptors in CD8+ T Lymphocytes.Front Pharmacol. 2020 Nov 30;11:576955. doi: 10.3389/fphar.2020.576955. eCollection 2020. Front Pharmacol. 2020. PMID: 33364951 Free PMC article.
-
Radiation-induced effects and the immune system in cancer.Front Oncol. 2012 Dec 17;2:191. doi: 10.3389/fonc.2012.00191. eCollection 2012. Front Oncol. 2012. PMID: 23251903 Free PMC article.
-
Chemotherapy broadens the range of tumor antigens seen by cytotoxic CD8(+) T cells in vivo.Cancer Immunol Immunother. 2012 Dec;61(12):2343-56. doi: 10.1007/s00262-012-1307-4. Epub 2012 Jun 20. Cancer Immunol Immunother. 2012. PMID: 22714286 Free PMC article.
-
Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia.Front Oncol. 2019 Oct 9;9:1004. doi: 10.3389/fonc.2019.01004. eCollection 2019. Front Oncol. 2019. PMID: 31649875 Free PMC article. Review.
-
Milk fat globule epidermal growth factor-8 blockade triggers tumor destruction through coordinated cell-autonomous and immune-mediated mechanisms.J Exp Med. 2009 Jun 8;206(6):1317-26. doi: 10.1084/jem.20082614. Epub 2009 May 11. J Exp Med. 2009. PMID: 19433619 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
